BACKGROUND: Two previous first-line studies showed an improved trend in response rate (RR) and progression free survival (PFS) in metastatic colorectal cancer (CRC) patients with KRAS mutation. Others have reported a worsened outlook for metastatic CRC patients with KRAS mutation and a higher likelihood of metastatic disease to the lungs. In this study, we aimed to address the impact of KRAS on the pattern of metastatic disease at presentation and on RR and PFS with first-line 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. METHODS: Patients with CRC who underwent KRAS testing using DxS assay at Roswell Park Cancer Institute (RPCI) were identified. Patients with metastatic CRC treated with first-line FOLFOX +/- bevacizumab were assessed for response and survival using RECIST 1.1 guidelines. A two-sided Fisher's exact test was used to determine the statistical significance. RESULTS: 181 patients with metastatic CRC and KRAS testing were identified. 83/181 patients were treated with FOLFOX (+/- bevacizumab) in the first-line setting at RPCI and were evaluable as per study guidelines. KRAS mutation (MT) occurred in 40.31% cases. There was no difference in organ-metastases distribution, RR (56.60% in KRAS wild-type (WT) and 50% in KRAS mutant) or PFS (9.3 months KRAS WT and 8.7 months in KRAS MT) based on KRAS status. CONCLUSION: In this single institute study, our findings do not support any predictive role for KRAS-MT in terms of response to FOLFOX first-line chemotherapy, or in terms of sites of metastatic disease at mCRC presentation.
BACKGROUND: Two previous first-line studies showed an improved trend in response rate (RR) and progression free survival (PFS) in metastatic colorectal cancer (CRC) patients with KRAS mutation. Others have reported a worsened outlook for metastatic CRC patients with KRAS mutation and a higher likelihood of metastatic disease to the lungs. In this study, we aimed to address the impact of KRAS on the pattern of metastatic disease at presentation and on RR and PFS with first-line 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. METHODS:Patients with CRC who underwent KRAS testing using DxS assay at Roswell Park Cancer Institute (RPCI) were identified. Patients with metastatic CRC treated with first-line FOLFOX +/- bevacizumab were assessed for response and survival using RECIST 1.1 guidelines. A two-sided Fisher's exact test was used to determine the statistical significance. RESULTS: 181 patients with metastatic CRC and KRAS testing were identified. 83/181 patients were treated with FOLFOX (+/- bevacizumab) in the first-line setting at RPCI and were evaluable as per study guidelines. KRAS mutation (MT) occurred in 40.31% cases. There was no difference in organ-metastases distribution, RR (56.60% in KRAS wild-type (WT) and 50% in KRAS mutant) or PFS (9.3 months KRAS WT and 8.7 months in KRAS MT) based on KRAS status. CONCLUSION: In this single institute study, our findings do not support any predictive role for KRAS-MT in terms of response to FOLFOX first-line chemotherapy, or in terms of sites of metastatic disease at mCRC presentation.
Entities:
Keywords:
FOLFOX; KRAS; cetuximab; metastatic colorectal cancer
Authors: W S Samowitz; K Curtin; D Schaffer; M Robertson; M Leppert; M L Slattery Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-11 Impact factor: 4.254
Authors: J L Bos; E R Fearon; S R Hamilton; M Verlaan-de Vries; J H van Boom; A J van der Eb; B Vogelstein Journal: Nature Date: 1987 May 28-Jun 3 Impact factor: 49.962
Authors: S Tortola; E Marcuello; I González; G Reyes; R Arribas; G Aiza; F J Sancho; M A Peinado; G Capella Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544
Authors: Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544
Authors: H Yamamoto; F Itoh; A Senota; Y Adachi; M Yoshimoto; T Endoh; Y Hinoda; A Yachi; K Imai Journal: J Clin Lab Anal Date: 1995 Impact factor: 2.352
Authors: V Bazan; M Migliavacca; I Zanna; C Tubiolo; N Grassi; M A Latteri; M La Farina; I Albanese; G Dardanoni; S Salerno; R M Tomasino; R Labianca; N Gebbia; A Russo Journal: Ann Oncol Date: 2002-09 Impact factor: 32.976
Authors: Jurriaan B Tuynman; Louis Vermeulen; Kristiaan J Lenos; Sander Bach; Leandro Ferreira Moreno; Sanne Ten Hoorn; Nina R Sluiter; Sanne Bootsma; Felipe A Vieira Braga; Lisanne E Nijman; Tom van den Bosch; Daniel M Miedema; Erik van Dijk; Bauke Ylstra; Ruth Kulicke; Fred P Davis; Nicolas Stransky; Gromoslaw A Smolen; Robert R J Coebergh van den Braak; Jan N M IJzermans; John W M Martens; Sally Hallam; Andrew D Beggs; Geert J P L Kops; Nico Lansu; Vivian P Bastiaenen; Charlotte E L Klaver; Maria C Lecca; Khalid El Makrini; Clara C Elbers; Mark P G Dings; Carel J M van Noesel; Onno Kranenburg; Jan Paul Medema; Jan Koster; Lianne Koens; Cornelis J A Punt; Pieter J Tanis; Ignace H de Hingh; Maarten F Bijlsma Journal: Nat Commun Date: 2022-08-04 Impact factor: 17.694
Authors: Jon Zabaleta; Borja Aguinagalde; José M Izquierdo; Nerea Bazterargui; Stephany M Laguna; Maialen Martin-Arruti; Carmen Lobo; José I Emparanza Journal: ISRN Surg Date: 2014-02-04